DSpace logo

Please use this identifier to cite or link to this item: http://142.54.178.187:9060/xmlui/handle/123456789/13026
Title: Hematopoietic effects of Azadirachta indica methanolic extract in cyclophosphamide mediated myelosuppressed albino rat
Authors: Nadeem Alvi, Muhammad
Tayyab Ansari, Muhammad
Ahmed Siddiqi, Faheem
Ishaque, Ambreen
Abbas, Muhammad
Ul-Hassan, Saeed
Keywords: Azadirachta indica
B19 virus
cyclophosphamide
filgrastim
myelosuppression
myelotoxicity
Issue Date: 8-Sep-2020
Publisher: Karachi:Pakistan Journal of Pharmaceutical Sciences, university of Karachi.
Citation: Alvi, M. N., Ansari, M. T., Siddiqi, F. A., Ishaque, A., & Abbas, M. (2020). Hematopoietic effects of Azadirachta indica methanolic extract in cyclophosphamide mediated myelosuppressed albino rat. Pakistan Journal of Pharmaceutical Sciences, 33.
Abstract: Myelosuppression or bone marrow suppression is one of the most common side effects caused by anti-cancer drugs. Certain nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics and viruses like B19 virus can also cause bone marrow suppression resulting in serious consequences like leukopenia, anemia and thrombocytopenia. Currently, it is mainly treated by Filgrastim, use of which is not without side effects. Certain natural drugs can be a safer alternative to treat myelosuppression. Azadirachta indica, commonly known as Neem, is an important medicinal plant of subcontinent. Keeping in view the traditional uses of Neem, present study aims to investigate its potential role in reversing myelosuppression. Albino rats were used to determine hematopoietic activity of Neem leaves after inducing myelosuppression by cyclophosphamide given subcutaneously. Filgrastim was used as reference standard to compare the antimyelosuppressant activity of the drug. The drug was evaluated in three doses i.e. 50mg/kg, 100mg/kg and 200mg/kg body weight, while blood samples were drawn on 0, 1st, 7th, 14th and 21st day. The drug was found to be effective in reversing bone marrow suppression in all three doses based on the hematological parameters (mean WBC, RBC, platelets, Hb, Hct etc.) which improved significantly. The results suggest that the drug can be used as antimyelosuppressant after establishing its safety and identifying its active constituents with their mechanism of action.
URI: http://142.54.178.187:9060/xmlui/handle/123456789/13026
ISSN: 1011-601X
Appears in Collections:Issue 5

Files in This Item:
File Description SizeFormat 
8-SUP-1531.htm147 BHTMLView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.